NCT03662724

Venetoclax Registry

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Hannover Medical School · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax

Detailed description

The aim of this study is to document all patients with AML who are treated with the BCL2 inhibitor Venetoclax outside a clinical trial in all hospitals participating in this registry study in a standardised manner. Data is collected retrospectively and multi-centric. It is neither a therapy study nor is the therapy influenced by this study. 1. Systematic and uniform collection and documentation of all patients treated with the BCL2 inhibitor Venetoclax. 2. Collection and integrative analysis of clinical data of included patients. 3. Mutation analysis of available patient samples and correlation with clinical parameters.

Conditions

• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	Venetoclax	Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.

Timeline

• Start date: 2017-11-01
• Primary completion: 2021-11-01
• Completion: 2025-11-01
• First posted: 2018-09-07
• Last updated: 2021-02-16

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study